Introduction
Patients with atrial fibrillation (AF) are at an increased risk for thrombosis, and anticoagulant therapy, preferably with a direct oral anticoagulant (DOAC) for most patients, is indicated for prevention of such events. 1 In contrast, patients with acute coronary syndromes (ACSs) or atherosclerotic cerebrovascular accidents (CVAs) and those who have undergone percutaneous coronary intervention (PCI) have an indication for antiplatelet therapy for prevention of arterial ischemic events. 2 The risk/benefit of either antiplatelet or anticoagulant therapy alone is clearly defined in the literature. 1, 2 The dilemma is that the use of anticoagulation in AF has historically excluded patients with indications for dual antiplatelet therapy (DAPT), and landmark ACS trials have likewise excluded patients requiring concurrent anticoagulation. [3] [4] [5] [6] Therefore, in the common situation where patients have indications for both antiplatelet and anticoagulant therapy, what should you do? How do you weigh the evidence for efficacy and safety (bleeding)? Both clotting factors and platelets interplay across all thrombotic situations, raising questions regarding the role of either reduced doses of DOACs or use of single antiplatelet therapy (SAPT) in situations where historic practice has been to use full-dose anticoagulants with DAPT therapy (triple therapy). The potential benefits and risks of adding anticoagulants in conditions such as ACS or stable coronary artery disease (CAD), traditionally managed with SAPT or DAPT, are also of interest. As such, our purpose is to provide an overview of the literature encompassing concomitant antiplatelet and DOAC therapy across a variety of indications most likely to affect pharmacy practice and to provide front-line clinicians with practical information to assist with the management of care. A glossary of terms is available online at www.cpjournal (Appendix 1). Table 1 has been developed as a resource and covers the following clinical situations [7] [8] [9] [10] [11] [12] :
• Among AF patients undergoing PCI, the use of standard or reduced-dose DOACs with antiplatelet therapy (Figure 1 ) • Among patients post-ACS without atrial fibrillation, the use of standard or reduceddose DOACs + DAPT • Among patients with stable CAD without AF, the use of reduced-dose DOAC ± acetylsalicylic acid (ASA)
Patients with AF and PCI -VASc score (Box 2), as well as the risk of stent thrombosis and coronary events, which is more difficult to quantify. Therapy selection must also respect the risk of bleeding in light of multiple antithrombotic therapies prescribed. 15 Patients with a high bleed risk will likely benefit more from reduced-dose regimens compared to their lowbleed-risk counterparts. The substantial bleed rates associated with traditional combination therapy (defined as triple therapy with warfarin + DAPT), however, have led to the investigation of strategies of reducedintensity anticoagulation or SAPT with anticoagulation with a focus on bleed rates ( Figure 1 ). RE-DUAL PCI examined the use of dabigatran + SAPT. 7 While it demonstrated a reduction in bleeding for both dabigatran + clopidogrel regimens relative to warfarin-based triple therapy, the trial design leaves clinicians with a level of uncertainty regarding the prevention of future events. Additionally, previous studies examining dabigatran have demonstrated a lack of protection for myocardial infarction, questioning the efficacy of dabigatran in a population at increased risk for future coronary events. 3 Rivaroxaban has also been studied in this population in PIONEER AF PCI, which examined varying regimens of rivaroxaban with either SAPT or DAPT. 8 inhibitor was used). In contrast, patients with a lower CHADS 2 score but higher cardiovascular risk (i.e., multivessel disease, ACS, etc.) may be more appropriately managed with low-dose rivaroxaban 2.5 mg BID + DAPT, due to the increased evidence for DAPT post-PCI and ACS. 8 Despite the reduction in bleeding demonstrated with both rivaroxaban regimens compared to warfarin-based triple therapy, the limitations regarding available efficacy data require the clinician to assess first the patient's bleed risk or ability to be managed with warfarin and second their different thrombotic risks. 
PRACTiCe TOOL
Practices today tend to consist of a warfarinbased triple therapy regimen of shorter duration or the combination of rivaroxaban 15 mg daily + clopidogrel 75 mg daily in the vast majority of these patients. However, options with apixaban will emerge with the recently published AUGUSTUS trial. 9 This trial was designed to address 2 different questions-comparing the use of apixaban (dosed as per the AF indication) in combination with clopidogrel to warfarin plus clopidogrel and examining both of these anticoagulation strategies with and without ASA. Ultimately, 4 combinations were addressedapixaban with SAPT, apixaban with DAPT, warfarin with SAPT and warfarin with DAPT. The use of apixaban (as opposed to warfarin) resulted in a significant reduction in bleeding in combination with SAPT or DAPT. The design of this trial allowed the investigators to determine that the removal of ASA (use of anticoagulation in combination with SAPT rather than DAPT) further decreased bleeding. So, within this trial, the use of apixaban and clopidogrel had the lowest bleeding rates and warfarin, clopidogrel and ASA the highest. This trial shares the limitations of other trials with respect to assessment of efficacy. Although the combined secondary endpoint of death or hospitalization favoured apixaban over warfarin, there was no difference detected for the combined endpoint of death or ischemic events, creating uncertainty as to the relevance of the hospitalization endpoint. In Canada, the rivaroxaban 2.5 mg tablet has been approved for use only in stable CAD; PRACTiCe TOOL however, you may see it used in combination with DAPT, targeting the patient subgroup that has more value placed on cardiovascular risk/ stent thrombosis. Apixaban, as dosed in the AUGUSTUS trial, is approved for use for AF; therefore, a regimen including apixaban at standard dosing for AF in combination with a P2Y 12 inhibitor is likely to be commonly used in the setting of AF with ACS/PCI, given bleeding was significantly reduced.
The CCS 2018 focused update on the use of antiplatelet therapy provides some additional considerations and recommends that the risks and benefits be balanced using clinical judgement. 2 Among this group of patients with AF undergoing PCI, risk stratification is also based on the urgency/findings of the PCI. Patients having PCI performed emergently due to an ACS or who have more problematic findings during the procedure are more likely to have a longer duration of antiplatelet therapy (6 months vs 3 months). In contrast, those having elective PCIs are more likely to have the antiplatelet regimen changed earlier (1 or 3 months). Regardless of the timing of the change in antiplatelet therapy, it is paramount that the pharmacist 1) ensure alteration of antiplatelet therapy at the decided time point and 2) ensure anticoagulant therapy for stroke prevention is adjusted, where applicable, to reflect applicable dosing for the indication of AF.
ACS without AF
Bottom Line: Standard therapy with DAPT is recommended but some patients at high thrombotic risk may be prescribed rivaroxaban 2.5 mg BID with DAPT. Meta-analyses examining the use of ASA + warfarin in patients with recent ACS and no indication for anticoagulation therapy reported this combination as reducing thrombotic events compared to ASA alone. However, this benefit was largely outweighed by an increase in bleeding events. [15] [16] [17] With DOACs showing similar or potentially lower major bleeding events in comparison to warfarin, new trials have reexamined combination therapy in an ACS population. 10, 11 These trials have been powered for efficacy compared to standard DAPT therapy and, as a result, are also able to appropriately assess bleed rates. APPRAISE 2 and ATLAS ACS 2-TIMI 51 examined the addition of apixaban or rivaroxaban, respectively, to DAPT in the setting of ACS.
10,11 APPRAISE 2 was stopped early due to excess bleeding, and the apixaban regimen is not recommended for this reason. 11 ATLAS ACS 2-TIMI 51, studying 2 regimens of rivaroxaban, reported an increased risk of bleeding for minimal benefit among a population at low risk of bleeding (Table 1) . 10 Therefore, standard therapy with DAPT is recommended, but some patients at high thrombotic risk may be prescribed this additional therapy.
Stable CAD without AF
Bottom Line: ASA alone is recommended for most patients, with the combination of rivaroxaban 2.5 mg BID plus ASA reserved for patients at high thrombotic risk. Even with medical therapy, patients with stable CAD continue to have a 5% to 10% risk of recurrent thrombotic events each year. 18 Previous studies examining the use of warfarin with or without ASA to further reduce risk in stable CAD provided evidence of decreased events but with an increased risk of bleeding, including intracranial hemorrhage. 19 The COMPASS trial studied rivaroxaban therapy 2.5 mg BID with ASA vs rivaroxaban 5 mg BID vs ASA alone and examined efficacy outcomes to assess the risk reduction of this additional therapy. 12 However, due to previous warfarin studies showing an unacceptable level of additional harm, it was also important to assess the risk of bleeding. The addition of rivaroxaban in the setting of stable CAD demonstrated benefit but with increased bleeding in a low bleed risk population. The additional bleeding events in a low-risk population make rivaroxaban 2.5 mg BID with ASA most appropriate for patients with a low baseline bleed risk who have a high risk of future thrombotic events (e.g., multiple vascular risk factors), including those whose only treatment option for CAD is maximal medical therapy as other interventions (e.g., stent placement or surgery) are not appropriate.
Role of the community pharmacist to improve patient outcomes
With the wide variety of anticoagulant/antiplatelet regimens, community pharmacists are well positioned to ensure appropriate management, given they are accessible (having patient encounters with refill prescriptions) and aware of all prescription therapies. Specific to combination antithrombotic therapies, there are PRACTiCe TOOL several important key patient counselling elements (Table 2 ). It is important that the indication for each component of therapy, as well as intended duration, be clearly identified at the initiation of therapy-if at the point of receiving a new prescription for an anticoagulant/antiplatelet combination uncertainty is expressed, clarification should occur with the prescriber. Reassessment of the appropriateness of this plan should occur at refill intervals through monitoring and updating medical conditions that may impact therapies, including but not limited to major or minor bleeding, thrombotic events and changes to renal function. Routine assessment should include pharmacokinetic interactions for the P2Y 12 inhibitors, including but not limited to CYP 3A4 (i.e., some anticonvulsants, azole antifungals, etc.), P-glycoprotein inhibitors (i.e., cyclosporine), and other CYP 450 enzymes. In addition, pharmacodynamic interactions that may increase bleed risk should be considered, such as antiplatelet agents or nonsteroidal anti-inflammatory drugs previously prescribed or self-selected as over-the-counter products. 
BOX 3 Trial design and endpoints
• A larger number of patients are required to reliably detect smaller differences between groups or those endpoints occurring less frequently.
• Given that bleeding occurs more commonly than thrombosis among patients prescribed antithrombotic agents, trials designed to primarily assess bleeding (safety) do not have enough patients to assess thrombosis (efficacy):  For AF patients undergoing PCI, trials assessing anticoagulant/antiplatelet combinations are only able to make conclusions about bleeding (safety endpoint) and not about efficacy.  For the indication of ACS or stable CAD, trials examining the addition of chronic anticoagulation were designed to make conclusions about efficacy and safety.
BOX 4 Interpreting bleeding
• Comparing bleeding rates between trials is problematic given that trials used different bleeding definitions and enrolled patients with different baseline risks for bleeding.
• Major bleeds can be catastrophic, resulting in mortality, intensive care admissions or extended hospital stays. All trials included these bleeding events.
• Clinically relevant nonmajor bleeding (CRNMB) affects the quality of life for our patients and consists of emergency room treatment, physician intervention to stop bleeding or temporary or permanent discontinuation of antithrombotic therapy. Relative to major bleeding, CRNMB occurs more frequently. Importantly, not all trials measured this type of bleeding.
PRACTiCe TOOL
Patients need to be engaged in the management of these more complex regimens to ensure optimal care delivery. The pharmacist can play a central role in this process, with regular assessments at each refill and through appropriate follow-up with other health care providers.
Summary
With a plethora of new evidence emerging for antithrombotic therapies and the use of DOACs with antiplatelet therapy, the community pharmacist will play an important role in ensuring safe and optimal use of these therapies. 
